anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method of treating and reducing a drug dependency such as a nicotine dependency is provided. The method comprises initially administering to a subject a drug, such as nicotine or another agonist of the drug in an amount which would normally provide the desired pharmacologic effects and at least partially satiate the needs for the drug by a user. The method also comprises administering to the subject an antagonist to the drug or its other agonist in an amount sufficient to at least partially block the pharmacologic effects of the drug or its other agonist while there is a substantial amount of the drug or other agonist present in the system of the user. In one embodiment of the invention, the drug and the antagonist are administered substantially simultaneously so as to occupy a substantial portion of the receptors of the user for that drug thereby blocking or attenuating the effects of any further intake of the drug or other agonist. In another embodiment, the drug or its other agonist is first administered and the antagonist is self-administered by a subject in a manner which mimics the use of the drug thereby counter-conditioning the drug user to the stimuli associated with the normal administration of the drug. The invention further provides a method of therapeutically treating psychophysiologic diseases and disorders involving neuronal dysregulation. The method additionally provides a pharmacologic composition for the treatment and reduction of drug dependence and which relies upon a combination of an agonist and an antagonist.
Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
The cosmetic topical formulation of this invention is directed toward diminishing skin wrinkling, fine line, improving skin tone, and combinations thereof. Preferably, the topical formulation contains a matrix metalloproteinase inhibitor, MMPI, and advantageously includes a natural estrogen, e.g., a true estrogen compound, such as 17-beta estradiol, or an estrogen-like steroid, (such as various phytoestrogens found in herbal preparations), as opposed to a synthetic estrogen. Other forms of the cosmetic topical formulation of this invention include combinations of synthetic estrogen and MMp inhibitor. Exemplary synthetic estrogens include, but are not limited to, ethynil estradiol and clomiphine citrate. The cosmetic topical formulation is safe and effective diminishing wrinkling, and improving skin tone. Certain compositions of this invention are useful for minimizing photodamage to skin, while in other embodiments, the composition according to this invention is useful to prevent or minimize the adverse effects on skin induced by cigarette smoking.
FIELD: chemistry. ^ SUBSTANCE: invention refers to compositions for skin improvement. The invention concerns the composition containing 0.01 to 30% cross-linked silicon elastomer at total mass of the composition; 0.1 to 20% zinc oxide at total mass of the composition where average particle size of zinc oxide is 300 nm and less; 0.1 to 5% reflective inorganic substance of plate-like particles at total mass of the composition where average particle size is 10000 to 30000 nm containing particles coated with mica titanium dioxide; cosmetically acceptable carrier system. The disclosed composition is characterised with out-of-focus and luminosity properties improving the skin. ^ EFFECT: there is ensured good coat layer over defects, such as pores and colour non-uniformity with maintaining natural skin appearance. ^ 11 cl, 2 ex, 4 tbl
New medicaments for the treatment of epilepsy and, opt headaches and circulatory disorders contain petrosal bone material from the skull of pigs and/or cattle, or an extract thereof, opt together with usual pharmaceutical formulation materials. The bone material is the petrous portion of the temporal bone. It is pref used in dried and powdered form. The bone material can be obtd from the heads of slaughtered pigs. The two bones obtd from each skull are about 2cm in length, 1cm in width and 0.5cm in height. They are cartilaginous in appearance, and are located in the region of the auditory organs. Effective antiepileptic agents which are free from side-effects.
In a 2-year carcinogenicity study in Sprague Dawley rats, mometasone furoate demonstrated no statistically significant increase in the incidence of tumors at inhalation doses up to 67 mcg/kg (approximately 1 and 2 times the maximum recommended daily nasal dose [MRDID] in adults [400 mcg] and children [100 mcg], respectively, on a mcg/m2 basis). In a 19-month carcinogenicity study in Swiss CD-1 mice, mometasone furoate demonstrated no statistically significant increase in the incidence of tumors at inhalation doses up to 160 mcg/kg (approximately 2 times the MRDID in adults and children, respectively, on a mcg/m2 basis). 

Mometasone furoate increased chromosomal aberrations in an in vitro Chinese hamster ovary-cell assay, but did not increase chromosomal aberrations in an in vitro Chinese hamster lung cell assay. Mometasone furoate was not mutagenic in the Ames test or mouse-lymphoma assay, and was not clastogenic in an in vivo mouse micronucleus assay and a rat bone marrow chromosomal aberration assay or a mouse male germ-cell chromosomal aberration assay. Mometasone furoate also did not induce unscheduled DNA synthesis in vivo in rat hepatocytes. 

In reproductive studies in rats, impairment of fertility was not produced by subcutaneous doses up to 15 mcg/kg (less than the MRDID in adults on a mcg/m2 basis).
Participants will be provided with standard information about the benefits of STSC and breastfeeding and will be encouraged to come into the NICU every day for at least 1 hour of STSC. To facilitate increased let down of breast milk, all participants will be provided a hospital grade breast pump free of charge during the stay of their babies in the NICU and assistance will be provided to the mothers in procuring a Medicaid covered breast pump to keep when the baby leaves the NICU. The hospital grade breast pump will be provided to her as soon as she enrolls into the study and will remain with her until her baby is discharged or transferred.
PURPOSE: A pharmaceutical composition or functional food composition containing 1,3-dipalmitoyl-2-oleoylglylcerol is provided to effectively suppress behavioral abnormality due to neural damage. CONSTITUTION: A composition for preventing or treating brain diseases contains 1,3-dipalmitoyl-2-oleoylglycerol of chemical formula 1 as an active ingredient. The brain diseases are cerebral infarction, cerebral edema, cerebral ischemia, vascular dementia, or memory impairment. A functional food composition for treating brain diseases contains the compound of chemical formula 1 as an active ingredient. The compound of chemical formula 1 is prepared by extracting and isolating from rice bran oil, sesame oil, olive oil, or grape seed oil. The daily dosage of the pharmaceutical composition by oral administration is 0.0001-100 mg/kg.
PURPOSE: A micro-needle massage patch and a method for manufacturing the same are provided to prevent twisting or bending and to ensure excellent air permeability. CONSTITUTION: A micro-needle massage patch contains a fiber and a soluble material(200). The massage patch is formed by mixing fibers(300) of a linear structure with the soluble material. The content of the fiber is 1-80 wt% based on the weight of the massage patch. The massage patch is formed by applying fibers forming a sheet on the soluble material. The fiber is a non-woven fabric, a fabric, or a mesh type. A method for fabricating the massage patch comprises: a step of mixing the fibers of a linear structure in a solution in which the soluble material is dissolved; a step of applying the solution on a micro-needle mold; a step of drying the solution on the mold and forming the massage patch; and a step of separating the massage patch from the mold.
The type of study planned is randomized controlled experimental design. The study group is divided into two as intervention and control groups. The intervention and control groups will be selected by simple random sampling method from among the volunteer participants who meet the inclusion criteria. Power analysis was performed to determine the sample size. It was observed that the effect size obtained in the reference study (Chow et al. 2017) was quite strong (d=0.96). As a result of the power analysis we performed, assuming that a lower level of effect size could be obtained (d=0.8), it was calculated that 80% power could be obtained at the 95% confidence level when at least 52 people (at least 26 people for each group) were included in the study. Considering that there may be data losses, the sample size was planned as 72 people (36 people for each group), taking approximately 30% more than the number of samples calculated as a result of the power analysis.
Patients with accelerated or blastic phase CML receive bosutinib PO QD and axitinib PO BID for 3 months. Courses repeat every 3 months in the absence of disease progression or unacceptable toxicity.
15q24.1 microdeletion syndrome is a recently described condition often resulting from non-allelic homologous recombination (NAHR). Typical clinical features include pre and post-natal growth retardation, facial dysmorphism, developmental delay and intellectual disability. Nonspecific urogenital, skeletal, and digit abnormalities may be present, although other congenital malformations are less frequent. Consequently, only one case was reported prenatally, complicating the genotype-phenotype correlation and the genetic counseling. We identified prenatally a second case, presenting with cerebral abnormalities including hydrocephaly, macrocephaly, cerebellum hypoplasia, vermis hypoplasia, rhombencephalosynapsis, right kidney agenesis with left kidney duplication and micropenis. Genome-wide aCGH assay allowed a diagnosis at 26 weeks of amenorrhea revealing a 1.6 Mb interstitial deletion on the long arm of chromosome 15 at 15q24.1-q24.2 (arr[GRCh37] 15q24.1q24.2(74,399,112_76,019,966)x1). A deep review of the literature was undertaken to further delineate the prenatal clinical features and the candidate genes involved in the phenotype. Cerebral malformations are typically nonspecific, but microcephaly appears to be the most frequent in postnatal cases. Our case is the first reported with a frank cerebellar involvement.
PURPOSE:To obtain an oxygen blocking agent, containing glycerol or an oligomer thereof and a surfactant, capable of coating the surface of polymerization curable type acrylic resins susceptible to inhibition of polymerization with oxygen in air and promoting the curing thereof. CONSTITUTION:An oxygen blocking agent containing glycerol or an oligomer thereof (e.g. diglycerol or triglycerol) and a surfactant (e.g. an alkylbenzenesulfonate). The aforementioned oxygen blocking agent is applied to the surface of a polymerizable polymerization curable type alkyl-based resin using an acrylic monomer to polymerize the resin. Thereby, unpolymerizability is prevented from occurring and smooth surfaces can be obtained. That is the surface of the resin can be cut off from oxygen to promote the curing thereof.
The present invention discloses novel medicine for treating acute tendon injury and a preparation method thereof. The medicine is prepared from notoginseng, dragon's blood, myrrh, frankincense, adlumidin, pyrite (prepared), peach seed, safflower, grassleaf sweelflag rhizome, mongolian dandelion herb, rhubarb and ground beeltle. In the main method of preparation, the notoginseng, the pyrite (prepared), the frankincense, the myrrh and the dragon's blood in the twelve kinds of traditional Chinese medicine are respectively pulverized into fine powder for backup; the safflower, the grassleaf sweelflag rhizome, the adlumidin, the peach seed, the rhubarb, the mongolian dandelion herb and the ground beeltle are decocted for two times by adding water, 10 times of quantity of water are added every time, the decoction is carried out for 1.5 hours, decoction liquid is merged and filtered, filtrate is concentrated into clear paste with the density of 1.20 (80 DEG C), the clear paste is dried, the five kinds of medical fine powder comprising the notoginseng, the pyrite (prepared), etc. are added and uniformly mixed, and 1000 granules are prepared after the components are granulated, dried and encapsulated. The medicine is a capsule, and has the functions of blood activation, pain alleviation and clot absorption. The medicine has the advantages of unique preparation method, obvious therapeutic effect on various kinds of traumatic injury, acute tendon injury and tumefaction pain, safety, high efficiency, convenient administration and no toxic or side effect, and the total effective rate is as high as 95%.
Adult patients (\>18 years old) were eligible for the study if they were undergoing elective or emergency cardiac surgery requiring CPB and aortic cross clamp. Exclusion criteria were patients with preoperative chronic renal insufficiency (Serum creatinine \>1.6 mg/dl) or on dialysis, hyperkalemia (\>5.0 mEq/L), AKI detected up to 24 hours before the procedure; patients receiving contrast agents 72 hours before surgery, planned off-pump cardiac surgery, hypersensitivity, allergy or known intolerance to spironolactone and pregnancy. Patients that died during the surgical procedure or 24 hours after surgery were eliminated from the analysis, as well as patients that did not receive spironolactone during the postoperative period. Criteria for stopping spironolactone were serum potassium \>5.5 mEq/L, a serum creatinine level ≥2.5 mg/dL and urine output of \<0.3 ml/k/hr during 8 hours.

One day prior to the procedure, patients that met the inclusion criteria were invited to participate in the trial, signing an informed consent. Spironolactone was administered orally by a study investigator (100 mg 12-24 hrs before surgery); subsequently three further doses of 25 mg were administered orally in postoperative days 1, 2 and 3. Thus, a total 1 x 100 mg and 3 x 25 mg doses of spironolactone in the intervention group were be given. If the patient had not been extubated, spironolactone was administered nasogastrically. Oral drugs were delayed by up to 4 hours if extubation had just occurred. The patients that decided not to receive spironolactone were followed during the study period and considered as controls. Preexisting ACE inhibitor, angiotensin receptor blocker, or MR antagonist were not suspended before surgery.
The obesity epidemic continues to worsen worldwide, driving metabolic and chronic inflammatory diseases. Thiazolidinediones, such as rosiglitazone (Rosi), are PPARγ agonists that promote 'M2-like' adipose tissue macrophage (ATM) polarization and cause insulin sensitization. As ATM-derived small extracellular vesicles (ATM-sEVs) from lean mice are known to increase insulin sensitivity, we assessed the metabolic effects of ATM-sEVs from Rosi-treated obese male mice (Rosi-ATM-sEVs). Here we show that Rosi leads to improved glucose and insulin tolerance, transcriptional repolarization of ATMs and increased sEV secretion. Administration of Rosi-ATM-sEVs rescues obesity-induced glucose intolerance and insulin sensitivity in vivo without the known thiazolidinedione-induced adverse effects of weight gain or haemodilution. Rosi-ATM-sEVs directly increase insulin sensitivity in adipocytes, myotubes and primary mouse and human hepatocytes. Additionally, we demonstrate that the miRNAs within Rosi-ATM-sEVs, primarily miR-690, are responsible for these beneficial metabolic effects. Thus, using ATM-sEVs with specific miRNAs may provide a therapeutic path to induce insulin sensitization.
Prenatal depression has been associated with adverse neonatal outcomes including preterm birth and low birthweight. Potential underlying mechanisms for prenatal depression effects on prematurity and low birthweight involve the elevated sympathetic nervous system SNS and Hypothalamic Pituitary Adrenal HPA Axis function noted in depressed pregnant women. These may lead to increased uterine artery resistance and the resulting limited blood flow, oxygen and nutrients to the fetus. Moderate pressure massage therapy may reduce this problem in depressed pregnant women by decreasing SNS and HPA axis function, resulting in decreased uterine artery resistance, increased oxygen and nutrients to the fetus and lower prematurity and low birthweight. An alternative model being explored here is that moderate pressure massage may increase progesterone/estriol ratios, which counteract the negative cortisol effects on gestational age. Eighty pregnant women with depression symptoms will be recruited at approximately 20 weeks gestation and randomly assigned to a moderate pressure massage therapy or to a SHAM light pressure massage touch/attention control group. The women will receive 20-minute weekly massage therapy sessions from 20 to 30 weeks gestation. At 20 and 30 weeks gestation, depressed symptoms will be assessed using the CES-D, and saliva samples will be collected to assay alpha amylase as an SNS marker, cortisol as an HPA axis marker and progesterone and estriol levels. Maternal Doppler ultrasound will be conducted to assess the uterine artery resistance index as an estimate of uterine artery blood flow. Upon delivery, the mothers' medical charts will be reviewed to record gestational age and birthweight. The investigators are hypothesizing that the moderate pressure massage group will elicit an increase in progesterone/estriol ratios and decreases in alpha amylase and cortisol levels, which in turn will lead to reduced uterine artery resistance and a lower incidence of prematurity and low birthweight.
Benign hepatic adenomas are associated with oral contraceptive use, although the incidence of benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use (46). Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage (47, 48).

Studies from Britain have shown an increased risk of developing hepatocellular carcinoma (49-51) in long-term (greater than 8 years) oral contraceptive users. However, these cancers are extremely rare in the U.S., and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than one per million users.

.
Vitamin A esters are separated from glycerides by passing the mixture preferably dissolved in a non-polar solvent, over a mild substantially non-acidic, or a deactivated strong absorbent.  For the purposes of this invention the expression mild absorbent means any absorbent having an absorptive coefficient, the same as or less than deactivated magnesia, and strong absorbents are those having absorptive coefficients greater than deactivated magnesia.  Mild absorbents mentioned include sodium aluminium silicate (artificial zeolites) natural zeolites, calcium hydroxide, calcium phosphate and zinc carbonate.  Strong absorbents are deactivated by treatment with steam or a polar solvent.  The solvents used are those of weak eluting power, and are low in the eluotropic series being below benzene in the series.  Solvents mentioned include light petroleum, petroleum naphtha, hexane and cyclohexane.  It is preferred that after the adsorption step, the column should be washed with a further quantity of solvent which is then evaporated under vacuum to give a concentrate of vitamin A esters.  It is also of advantage if the starting mixture is given a preliminary distillation under reduced pressure before being subjected to the process of the invention. Examples are given using various combination of oils and various adsorbents.  Samples have been furnished under Sect. 2 (5) of (1) an ester concentrate obtained by dissolving a natural concentrate in petroleum ether and absorbing in aluminium silicate and re-extracting with petroleum ether.  (2) A triglyceride fraction obtained by subsequently electing the column obtained in sample (1) with ethyl ether, and evaporating the ether.
Cerebro-vascular accident is a destructive complication of sickle cell disease, CVA is a important cause of morbidity and mortality individuals with SCD, which cause motor and neurocognitive complications. The CVA pathophysiology can be described by vasculopathy and obstruction caused by the sickle erythrocytes with narrowing of cerebral vessels of the circle of Willis (middle cerebral artery, anterior cerebral artery, anterior communicating artery, internal carotid artery, posterior cerebral artery, and posterior communicating artery).

Patients with sickle cell disease develop vasculopathy and obstruction at specific sites as distal internal carotid artery (ICA) and the proximal segments of the middle cerebral artery (MCA) and anterior cerebral artery (ACA). This Study have been concerned to identify synchronous risk factors for Cerebro-vascular accident and the presence of increase in cerebral blood flow velocity (CBFV) in arterial parts of the polygon of Willis by transcranial doppler (TCD) has been confirmed as the important risk factor for the development of ischemic Cerebrovascular accidents in children and adolescents with SCA. TCD can detect intracranial arterial narrowing caused by arterial vasculopathy associated with SCA. TCD is a non-invasive, portable, and relatively inexpensive method that uses specific areas of the skull to access the intracranial arterial circulation and to measure CBFV in the polygon of Willis arteries, magnetic resonance Angiography (MRA), and cerebral angiography are available for cerebrovascular disease diagnosis.(5-8) However, TCD is due to its operator dependent, it has a narrow application area. Cerebrovascular disease indicates a group of disorders that alter the flow of blood in the brain. The brain's functions can be temporarily or permanently impaired as a result of this change in blood flow. Timely diagnosis and treatment can restore the brain-impaired functions, resulting in a much-improved prognosis for the patients. This review summarizes the basic principles underlying the TCD imaging technique and its utility as a diagnostic tool for cerebrovascular disease.
We investigated the effects of histamine and GABA A receptor agents on pain and depression-like behaviors and their interaction using a tail-flick test and the forced swimming test (FST) in male mice. Our data revealed that intraperitoneal administration of muscimol (0.12 and 0.25 mg/kg) increased the percentage of maximum possible effect (%MPE) and area under the curve (AUC) of %MPE, indicating an antinociceptive response. Intraperitoneal injection of bicuculline (0.5 and 1 mg/kg) decreased %MPE and AUC of %MPE, suggesting hyperalgesia. Moreover, muscimol by reducing the immobility time of the FST elicited an antidepressant-like response but bicuculline by enhancing the immobility time of the FST caused a depressant-like response. Intracerebroventricular (i.c.v.) microinjection of histamine (5 µg/mouse) enhanced %MPE and AUC of %MPE. i.c.v. infusion of histamine (2.5 and 5 µg/mouse) decreased immobility time in the FST. Co-administration of different doses of histamine along with a sub-threshold dose of muscimol potentiated antinociceptive and antidepressant-like responses produced by histamine. Cotreatment of different doses of histamine plus a noneffective dose of bicuculline reversed antinociception and antidepressant-like effects elicited by histamine. Cotreatment of histamine, muscimol, and bicuculline reversed antinociceptive and antidepressant-like behaviors induced by the drugs. The results demonstrated additive antinociceptive and antidepressant-like effects between histamine and muscimol in mice. In conclusion, our results indicated an interaction between the histaminergic and GABAergic systems in the modulation of pain and depression-like behaviors.